Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
NCT04925024
Recruiting
The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue... Read More
Gender:
All
Ages:
12 months and below
Trial Updated:
04/07/2024
Locations: Primary Children's Hospital/University of Utah, Salt Lake City, Utah
Conditions: Hypoplastic Left Heart Syndrome
Register for Updates
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Childhood Malignant Neoplasm
Register for Updates
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
04/05/2024
Locations: University of Utah Salt Lake City, Salt Lake City, Utah
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Register for Updates
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Recruiting
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Gender:
All
Ages:
99 years and below
Trial Updated:
04/05/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Childhood Malignant Neoplasm
Register for Updates
A Study to Assess EN3835 in the Treatment of Plantar Fasciitis (PFA)
NCT06169319
Recruiting
This study will assess the efficacy, safety, and tolerability of 2 different doses of EN3835 compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2024
Locations: Endo Clinical Site 5, Salt Lake City, Utah
Conditions: Plantar Fasciitis
Register for Updates
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
NCT06162611
Recruiting
Intrauterine devices (IUDs) are highly effective to prevent pregnancy when used for emergency contraception (following unprotected intercourse in the last 3 days), but data are lacking for people who desire an etonogestrel (ENG) contraceptive implant in this situation. This proposal will identify the most effective way to start an implant for emergency contraception using a randomized controlled trial comparing pregnancy risk between those receiving the implant vs. the implant plus oral emergenc... Read More
Gender:
Female
Ages:
Between 18 years and 35 years
Trial Updated:
04/04/2024
Locations: Planned Parenthood Association of Utah, Salt Lake City, Utah
Conditions: Emergency Contraception
Register for Updates
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
NCT05625633
Recruiting
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: University of Utah Midvalley Health Center, Salt Lake City, Utah
Conditions: Warts
Register for Updates
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
NCT05471908
Recruiting
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Gender:
All
Ages:
18 years and below
Trial Updated:
04/04/2024
Locations: Intermountain Primary Children's Hospital Larry H. and Gail Miller Family Campus, Lehi, Utah
Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Register for Updates
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
NCT05140941
Recruiting
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy. Treatment will be initiated during the second or third trimester in approximately 100 pregnant people. Maternal participants will take one SOF/VEL tablet once daily for 12 weeks (84 days) and followed until 12 weeks after treatment completion (postpartum). Infants will be followed from birth until one year of age. The primary objectives are to evaluate the... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
04/04/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Hepatitis C, Chronic, Pregnancy; Infection
Register for Updates
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Huntsman Cancer Hospital, Salt Lake City, Utah
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/04/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Neuroblastoma
Register for Updates
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124
Recruiting
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in in 2 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin af... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah
Conditions: Pneumococcal Disease
Register for Updates